Trial Profile
A Window-of-opportunity Study of Pelareorep in Early Breast Cancer (AWARE-1)
Status:
Discontinued
Phase of Trial:
Phase 0
Latest Information Update: 08 Feb 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Pelareorep (Primary) ; Letrozole; Trastuzumab; Trastuzumab
- Indications Adenocarcinoma; Early breast cancer; HER2 negative breast cancer; HER2 positive breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms AWARE-1
- Sponsors Oncolytics Biotech
- 09 Dec 2023 Results applying T cell receptor sequencing of matched tumor tissue and whole blood pre and post-treatment from this study to further explore the effects of pela therapy on TILs, presented at the 46th Annual San Antonio Breast Cancer Symposium
- 07 Dec 2023 According to an Oncolytics Biotech media release, data from this study were presented at The San Antonio Breast Cancer Symposium (SABCS) 2023.
- 07 Dec 2023 Results presented in an Oncolytics Biotech media release.